MIT’s cancer and infectious disease therapy spinout has added $40m to a round that will support the progression of its lead asset into the clinic.

The Qilu Pharmaceutical-backed cancer, immune disorder and metabolic disease drug developer has closed a series B round led by Lilly Asia Ventures.

The Progressive-backed digital banking technology provider has now secured at least $482m in total, with Russell Westbrook Enterprises leading its latest round.

The Livzon-backed cancer and infectious disease therapy developer has added $40m to a round that will support the progression of its lead candidate toward clinical trials.

Telstra and Standard Chartered Ventures helped the cloud security software provider hike its overall funding to about $185m.

The DevOps platform provider has raised $117m to date after Salesforce Ventures and Insight Partners co-led its latest funding round.

SoftBank has thrown its weight behind edtech developer Descomplica by co-leading an $84.5m round with Invus Opportunities.

The Kyrus-backed cybersecurity software developer has achieved $125m of total funding after Summit Partners led its series C round.

The automotive vision technology developer raised $48.9m in a round featuring Continental, Toyota AI Ventures, BMW i Ventures, Robert Bosch Venture Capital and Fluxunit – Osram Ventures.

University of Oxford and OSI have both returned for a $95.4m series C round that also included GV and, through the conversion of a note, Eli Lilly.